T he term paradigm was introduced into science and philosophy by Thomas Kuhn in 1962 to refer to the set of concepts that define particut t lar scientific thinking during a given period of time. 1 The term refers to the predominant worldview in a part t ticular realm of human thought. Kuhn hypothesized that paradigm shifts occur when new and more accurate theories (which represent approximations of the undert t standing about a topic) replace earlier, less comprehent t sive theories.
T he term paradigm was introduced into science and philosophy by Thomas Kuhn in 1962 to refer to the set of concepts that define particut t lar scientific thinking during a given period of time. 1 The term refers to the predominant worldview in a part t ticular realm of human thought. Kuhn hypothesized that paradigm shifts occur when new and more accurate theories (which represent approximations of the undert t standing about a topic) replace earlier, less comprehent t sive theories.
The medical intervention known as blood transt t fusion is associated with both beneficial effects and adverse events in recipients. Over the past 100 years, transfusion medicine has experienced many challenging periods resulting in the introduction of improvements in technology to increase the safety of allogeneic blood transfusion. There have thus been six major paradigt t matic shifts associated with transfusion medicine scit t ence and technology (Table 1) . Conceptual and technot t logical developments in transfusion medicine are thus ongoing processes and more paradigm shifts are to be expected in the future. These may include modification of the red blood cell (RBC) surface to reduce antigenict t ity 11, 12 and the development of novel ways to produce the improvement of transfusion medicine technology is an ongoing process primarily directed at increas--ing the safety of allogeneic blood component transfusions for recipients. over the years, relatively little attention had been paid to the leukocytes present in the various blood components. the availability of leukocyte removal (leukoreduction) techniques for blood components is associated with a considerable improvement in various clinical outcomes. these include a reduction in the frequency and severity of fe--brile transfusion reactions, reduced cytomegalovirus transfusion-transmission risk, the reduced incidence of alloimmune platelet refractoriness, a possible reduction in the risk of transfusion-associated variant creutzfeldt-Jakob disease transmission, as well as reducing the overall risk of both recipient mortality and organ dysfunction, particularly in cardiac surgery patients and possibly in other categories of patients. internationally, 19 countries have implemented universal leukocyte reduction (ulr) as part of their blood safety policy. the main reason for not implementing ulr in those countries that have not appears to be primarily concerns over costs. nonetheless, the available international experience supports the concept that ulr is a process that results in improved safety of allogeneic blood components. blood products in vitro (for example, RBCs). 13 Considerable progress has been made over the past two decades to reduce the risk of the adverse events associated with the transfusion of blood components. However, significant transfusiontassociated morbidity and mortality remain a problem. 14t17 Recent data from various hemovigilance systems worldwide showed that the most common causes of transfusiontassociated mortality include transfusiontrelated acute lung injury (TRALI), ABO hemolytic transfusion events, and bact t terial sepsis associated with the transfusion of bacteria present in contaminated blood components (Tables  2, 3 ). The number of transfusiontassociated mortalt t ity cases reported annually increased considerably over the past 30 years, which is probably mostly related to increased recognition of such events as being transfut t siontassociated. As can be seen in both Tables 2 and 3 , TRALI has become the most commonly reported cause of transfusiontassociated mortality.
Why implement universal leukoreduction?
The transfusion transmission risk of many pathot t gens has been greatly reduced by the development of int t creasingly sensitive screening methods; however, transt t fusionttransmitted infections still occur. Transfusiont related infections continue to be reported as tests for many known pathogens are not yet available or not bet t ing used. 18t22 In addition, the ongoing emergence of new agents demonstrates that potential threats to the blood supply will continue to emerge worldwide.
Potential adverse effects associated with the transfut t sion of blood components containing donor leukocytes and their soluble biological mediators, such as cytot t kines, are known to have a number of biologic effects associated with transfusion. 23 Leukocytes with their specific allogenic structure (the HLA class I and class II 
1950
Carl walter and w.p. Murphy introduce the plastic bag for blood collection and component preparation, replacing breakable glass bottles with durable plastic bags and most importantly allowing sterile blood component preparation. 4, 5 1960 to 1980 post transfusion viral infections became a major concern affecting the blood recipient, resulting in the development and implementation of effective screening methods to reduce pathogen transmission. 6, 7 1990 leukocyte reduction of blood components are shown to be associated with improved clinical outcome, which lead to the implementation of ulr in many countries. 
to 2010
Development of pathogen inactivation (reduction) technology to reduce the risk of pathogen transmission by blood components. This will lead to the development of pathogen inactivation technologies to treat the various cellular blood components to further improve blood safety. antigens on their surface) appear to be the main targets of a recipient' s immune system. In addition, some vit t ruses can be transmitted as they exist within leukocytes (i.e. CMV, HHVt8, and HTLVtI/II). Another, not so well characterized effect of transfused leukocytes, is the potential modulating influence on the recipient' s imt t mune system. 2 Leukocyte reduction is typically defined as a blood processing step for reducing the leukocyte content of whole blood, RBCs, or platelet units down to 5×10 6 (1×10 6 in Europe) residual WBCs per unit of component. Universal leukocyte reduction (ULR) is the routine application of the bloodtprocessing step to all units of whole blood, RBCs, and platelets prior to storage in a country or in a blood transfusion service. 25 To attempt to prevent the adverse effects of the leut t kocytes contained in blood components, several metht t ods have been developed to remove leukocytes from the various blood components. 25, 26 Leukocyte reduction procedures can be performed either pretstorage at the blood collection facility, or posttstorage either at the hospital transfusion service or at the patient' s bedside just prior to transfusion. 27 Pretstorage leukocyte ret t duction of cellular blood components removes donor WBCs before they undergo apoptosis or necrosis and before they release breakdown products or cytokines.
The removal of leukocytes from various blood comt t ponents can be associated with several improved clinical outcomes (Table 4) . These outcomes, subdivided as to whether each benefit has been proven by evidencetbased guidelines to be clinically relevant, likely to be clinically relevant, and of unproven benefit (i.e. those that can be considered only of theoretical relevance). 8 The major disadvantages associated with leukocyte Table 4 . putative clinical benefits of leukocyte reduction, subdivided as to whether the benefit has been proven by evidence-based guidelines to be relevant clinically, likely relevant clinically, or clinical relevance is unproven.
reduction are cost and logistics. 28 The report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) published in 1998 concluded that ULR of both platelets and RBCs would add a sigt t nificant expense to the Canadian health care system, but that leukocyte reduction of all transfused platelets might be cost effective. 24 As a result, leukocyte reduct t tion of all platelets was introduced in Canada during the first quarter of 1998. Leukocyte reduction of RBCs was only introduced subsequently and ULR for all blood products was fully implemented in Canada in July 1999. 29 There is some loss in product potency associated with leukoreduction technology, although, at the prest t ent time, for RBCs this is unlikely to cause an increased demand for RBC transfusions because of the concurt t rent increase in the volume of whole blood collections that offsets this loss in product potency. With regard to the loss in platelet potency, there is considerable unt t certainty about the proper therapeutic dose of platelets, such that a 10% to 15% quantitative reduction is unt t likely to be noticeable clinically. As in the case of RBCs, the increase in whole blood collections will also likely increase platelet potency of whole bloodtderived platet t lets by negating the 11% filtration effect. 30 Adverse effects associated with the use of leukocyte reduction filters have been reported. 31t33 The reported severe hypotensive reactions to leukocyte reduced blood components have been associated mainly with the transfusion of blood components filtered at the bedt t side. 34 These reactions are attributed to the generation of bradykinin and possibly other vasodilators, as dot t nor plasma passes over the filter media. 35, 36 Bradykinin generated during filtration has a short halftlife and is therefore biologically active only on direct intravenous administration. Blood components that are leukocyte reduced by pretstorage filtration appear not to cause hypotensive reactions and current knowledge indicates that transfusion of these blood components is generally free from complications associated with the use of leut t kocyte reduction filters. 29 However, recent reports show that hypotensive reactions can occur even with the prestorage leukoreduction of blood products in which a defect in the metabolism of kinins may be a risk fact t tor. 37 The implementation of ULR has created some new requirements relating to the need to standardize and to quality control the whole process. 38 In our opinion the associated clinical benefits of leukocyte reduction nonetheless far overweigh the adverse features, and in the absence of considerations of cost, most transfusion medicine professionals would readily endorse a policy 
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Case series that use data from uncontrolled observations; or that represent unsubstantiated "expert" opinion.
to implement ULR by pretstorage filtration. Others argue that in the absence of adequate data suggesting universal benefit the technology should be applied set t lectively only to those patients who will clearly benefit from this intervention. 39 In the opinion of the authors, implementation of ULR will improve transfusion safety, which should ext t tend to all patients receiving blood components at the very least for the proven benefits of this intervention. Although patients who have not had a febrile nonthet t molytic transfusion reaction (FNHTRs), who are not receiving longtterm platelet transfusions, and are not at risk of developing symptomatic CMV disease may derive no immediate benefit from prestorage leukocyte reduction, it is possible that they may accrue tangible benefits in the future. There are also cost savings in ret t sources, time and effort associated with improvements in the efficiency of the transfusion service and nursing personnel, which will further reduce the net community cost.
The current practice of transfusion in Saudi Arabia and other countries around the world is selective leukot t cyte reduction. This review will thus present an upttot date review of the clinical issues associated with leukot t reduction and the level of evidence indicating the efficat t cy, the current international status and the international experience, that we hope will influence the decision to implement ULR.
Evidence-based clinical efficacy of leukoreduc--tion
Evidencetbased medicine has been defined as the intet t gration of best research evidence with clinical expertise and patient values. Various classifications of the differt t ent types of scientific evidence available, to establish the efficacy of a particular intervention, have been prot t posed. Table 5 provides such a scheme for assessing the levels of medical and/or scientific evidence and is based on the various publications of Sackett and colleagues. 40 Many studies have been done to evaluate the efficacy of leukocyte reduction to prevent or reduce adverse effects caused by leukocytes present in blood components. The following sections review the evidence for various clinit t cal outcomes.
Non-hemolytic febrile transfusion reactions (NHfTR)
Historically, NHFTRs were thought to be associated with the presence in the recipient of antibodies to transt t fused allogeneic leukocytes. NHFTRs, the most comt t mon adverse effect of blood transfusions, are thought to be clinical manifestations of allotimmunization.
41
The minimum number and type of WBCs needed to generate a postttransfusion NHFTR in an alloimmut t nized recipient of blood components remains unclear. 42 Over the past decade, however, it has been established that most NHFTRs are due to cytokines present in the transfused blood components, having been elaborated during storage by the leukocytes. 43 Many studies make the point that the timing of filt t tration is important for reducing the rate of NHFTRs. The age of the blood component is also an accepted risk factor. The older the component is, the greater the liket t lihood of an adverse reaction. This is particularly the case for platelet concentrates, which are stored at higher temperatures (22±2°C) than RBC units. Thus, a more obvious cause for a transfusion reaction than the numt t ber of remaining leukocytes was postulated. 41, 44, 45 Since older blood components have greater amounts of cytokines, the accumulation of soluble cytokines ret t leased from leukocytes during storage may be the explat t nation for the higher rate of NHFTRs. 44,46t48 It seemed reasonable therefore that pretstorage of blood compot t nents would significantly reduce cytokine accumulat t tion during storage. Some clinical trials (not prospect t tive, randomized controlled trials) have demonstrated such effects of pretstorage filtration for RBCs 49 even in previously alloimmunized patients. 47 Many studies published after 1990 have addressed the incidence of febrile reactions in the context of leukocyte filtration (Table 6) . 26 All studies achieved a level of leukoreduct t tion of <5×10 6 leukocytes in the transfused blood comt t ponent.
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Until recently the role of leukoreduction in ameliot t rating the rate of NHFTRs had not been clearly estabt t lished. Several recent publications show clearly that leut t koreduction is associated with a significant reduction in the NHFTR rate (level 1 evidence) ( Table 7) . 8 The NHFTR rate following RBC transfusion was shown to be reduced by approximately 50%, from 0.35% to 0.18%.
50t52 Similarly, the pretstorage leukoreduction of platelets, which is generally associated with an approxit t mate frequency of a 30% rate of NHFTRs, has been shown to be reduced significantly by transfusing pret storage leukocyte reduced platelets.
50,51,53

Pathogen transmission
Viruses. Leukoreduction is a known effective strategy for reducing the risk of the transmission of celltassocit t ated viruses. The most prominent among these are the herpes viruses, particularly CMV, also known as hut t man herpes virus (HHV) 5. 54t60 CMV is transmitted by the leukocytes present in transfused blood compot t nents. To acquire CMV from a blood donor, a blood transfusion recipient must be exposed to donor WBCs that are latently infected with CMV. CMV then must be reactivated and the cell must survive long enough in the host to release infectious virus particles. 61 Several patient populations are at risk for serious morbidity as a result of transfusiontassociated CMV infection (TAt CMV), including low birth weight infants, some oncolt t ogy patients, allogeneic bone marrow transplant recipit t ents, but most particularly immunosuppressed patients. Early studies of TAtCMV indicate that the prevalence of postttransfusion CMV, without employing any pret t vention technology, may be as high as 30% per patient, depending upon the frequency of allogeneic blood comt t ponent transfusion. 62 CMVtseronegative cellular blood components have been the standard approach provided to CMVtseronegative patient populations at high risk for significant morbidity for primary CMV infections. 63 However, the increasing number of immunosuppressed patients who might benefit from receipt of such compot t nents, the high prevalence of CMV antibody in some blood donor populations, and the logistics of maintaint t ing multiple inventories of blood components have led to the exploration of pretstorage leukoreduction as an alternative strategy for the provision of "CMVtsafe" blood components. 57 The American Association of Blood Banks (AABB) has thus suggested that residual leukocyte levels less than 5×10 6 make a blood compot t nent "CMVtsafe". allogenic transfusions in these patients will reduce this postttransfusion CMV risk to approximately 1.3%. 58 In comparison, a recent study has shown that the use of pretstorage leukoreduced RBCs or platelet transfut t sions can reduce the risk of postttransfusion CMV to approximately 2.5%. 65 Over the years there have been a large number of studies examining strategies to pret t vent TAtCMV. Interpretation of some of these studies is difficult as many were not randomized, failed to use a control group, used historical controls, or were retrot t spective. 57 Nonetheless, the balance of the evidence from the available clinical studies suggests that acceptable CMV safety can be achieved by pretstorage leukoreduction. Although it is likely that leukoreduced blood compot t nents are effective in reducing the risk of TAtCMV, there is insufficient evidence at this time to firmly rect t ommend the discontinuation of CMV testing even in the face of ULR.
66 Considerable debate thus exists as to whether leukoreduction and the use of serologically negative CMV allogenic transfusion can be considered equivalent. A recent (2001) Canadian consensus cont t ference that has examined this issue in detail recomt t mended that hightrisk patients (i.e. allogenenic bone marrow transplant patients) receive leukoreduced blood products that are also seronegative for CMV. 61 A recent study provides strong evidence (level 2 evidence) that human herpes virus 8 (HHVt8) can be transmitted by allogeneic transfusion, particularly in high prevalence geographic regions. 67 Based on the ext t perience with CMV, it is likely that pretstorage leukot t cyte reduction may prevent the transmission of HHVt 8 due to its WBCs associated nature. HHVt8 can cause a lifelong infection, with periodic reactivations, during which virus may circulate in peripheral blood WBCs and be transmissible through transfusion (level 5 evit t dence). 68 For other viruses such as EpsteintBarr virus (EBV), human Ttcell lymphotrophic virus type I and II (HTLV I and II), no conclusive studies exist that demonstrate a similar efficacy of virus removal by leukoreduction as seen for CMV. Some experimental in vitro studies indit t cate a significant reduction of HTLV I virus from blood components by pretstorage leukoreduction but the pret t vention of clinical HTLV I infections with leukoreduct t tion in humans has not been proven. 69 Nonetheless, it is reasonable to assume that leukoreduction adds more safety to transfusion of blood components, since not all HTLV I infected donors express HTLV I antibodt t ies. 70 Bacterial/protozoal infections. Bacterial contaminat t tion of blood components can result in a severe comt t plication of allogeneic blood transfusion in recipients. The risk of contaminated pooled platelet transfusion has been estimated to be as high as 2% (asymptomatic cases) since platelet concentrates are stored at room temperature (a temperature that facilitates bacterial growth) to preserve their viability and function. 71t73 Asymptomatic bacteremias and/or infections in a dot t nor and the ability of Yersinia enterocolitica to grow at low temperatures in an irontrich environment such as in stored RBC components makes Y entercolitica the most commonly encountered serious bacterial contamit t nant associated with RBC transfusion. 74, 75 Several studt t ies have demonstrated that the bacterial overgrowth of blood components by Y enterocolitica inoculated into blood components under experimental conditions is dit t minished or prevented by pretstorage leukoreduction, after a room temperature holding period. 75, 76 One way of reducing the risk of bacterial contamination in platelet concentrates is to reduce the level of leukocytes present. Filtration to remove leukocytes does not prevent bactet t rial growth, although it can reduce the level of bacterial contamination for some organisms. This process is not effective against some species of bacteria (for example, S epidermidis). This method, therefore, does not provide full protection against the risk of bacterial contaminat t tion, but has been shown to significantly reduce the risk of transfusiontassociated sepsis. 77 The mechanisms by which leukoreduction removes bacteria are complex and several possibilities have been proposed, based on experimental data. First, bacteria are phagocyted during the proposed 8thour storage of blood at ambient temperatures and then removed with the leukocytes upon leukoreduction. Secondly, bacteria are adsorbed directly by the filter matrix or indirectly by binding to leukocytes and platelets or on activated complement components, which are removed by negat t tively charged filters.
78
Recent data from the Hemovigilance Network in France clearly indicates that the bacterial sepsis rate, as the percentage of all transfusion event rates, was signifit t cantly reduced (1.7% versus 3.8%) following the implet t mentation of ULR in France compared with before the implementation of ULR (Table 8) . 79 Of particular relt t evance is the fact that 1 in 3000 cellular blood compot t nents have been shown to contain bacteria. 77 The risk of the transmission of Trypanosoma cruzi, the causative agent of Chagas' disease, which is common in South America, but rare in other parts of the world, was shown to be decreased by leukoreduction, in an ext t perimental study in susceptible mice. 80 
Variant CrutzfeldtrJacob Disease transmission (vCJD).
vCJD is a major concern of the transfusion medicine community, because infectivity can be detected in the lymphoreticular system as well as in blood. 81 Evidence from an immunodeficient animal model of scrapie sugt t gests that host lymphocytes and/or follicular dendritic cells play a role in peripheral neuroinvasions. 82, 83 The abnormal prion protein PrPSc of vCJD has been det t tected in lymph nodes, tonsillar tissue, spleen and the appendix in clinical cases of vCJD. 84 Animal studies have shown that B lymphocytes might play a key role in disease transmission. 85 In several countries, part t ticularly in western Europe, ULR was instituted over the past 6 years in an attempt to reduce the theoretit t cal risk of vCJD transmission via transfusion of allot t geneic blood and blood components. 86, 87 Four cases of probable transfusion transmission of vCJD infection have recently been diagnosed in patients in the United Kingdom. All four cases had received transfusions of nontleukoreduced RBCs between 1996 and 1999 from donors who developed symptoms of vCJD after blood donation. These four cases of vCJD infection associated with blood transfusion increases the level of concern about the possible risk of vCJD transmission between humans by blood transfusion, although much remains unknown. This concern reinforces the importance of the existing precautions that have been introduced to reduce the risk of transmission of vCJD infection by blood and blood components. 88 Blood screening assays are currently under development but are not yet ready for application. 89 A recent study by Gregory et al, in a hamster model of bloodtborn transmissible spongiform encephalopathy (TSE) transmission, showed that filtrat t tion leukoreduction was associated with a reduced risk of TSE infection (from 48.1% to 31.5%). 90 The authors of this study showed that filtration leukoreduction was associated with reduced TSE infectivity, but that this intervention was not sufficient to remove all TSE int t fectivity. 91 Specific prion reduction filters for RBCs oft t fer the possibility of a further substantial reduction in vCJD infectivity and in the overall risk of vCJD transt t mission. However, concerns persist about how best to assess the efficacy of these technologies, since current assays are not sufficiently sensitive to detect infectivity in the blood of patients with clinical vCJD.
92
Alloimmunization and platelet refractoriness
Alloimmunization is defined as a recipient immune response against antigens on tissue from a genetically dissimilar donor. The direct allotrecognition pathway occurs when recipient Tthelper cells directly interact with class II molecules encoded by the major histocomt t patibility complex (MHC) on donor antigentpresentt t ing cells (APCs). This pathway is the strongest known stimulator of immunity and the one targeted for ret t moval by leukoreduction strategies. 93 The reduction in alloimmunization is a well documented beneficial effect of using leukoreduced blood component transfusions, and is especially important for repeatedly transfused patients and transplant recipients.
93t98 Table 9 provides a cumulative metatanalysis of seven randomized, cont t trolled trials which clearly showed that the relative risk of HLA alloimmunization can be reduced considerably through the use of leukoreduced blood components (level 1 evidence). In the years 1983 to 1995 there were seven reports whose cumulative relative risk reduction with the use of leukoreduced allogenic blood compot t nents was 0.32, with 95% confidence intervals of 0.18 to 0.56. These seven studies involved a total of only 418 patients. 8 In 1997, the TRAP study which examined the relative risk of HLA alloimmunization and platelet refractoriness in 400 patients provided level 1 evidence (a large randomized controlled trial) that the relative risk of HLA alloimmunization and platelet refractorit t ness with the use of leukoreduced blood components was statistically significant. 99 The cumulative relative risk reduction of HLA immunization for all the pubt t lished studies, following the use of leukoreduced blood components, was recently estimated to be 0.30 (95% confidence intervals; 0.20 to 0.46).
99
A recent retrospective analysis of 13 902 platelet transfusions in 617 Canadian patients undergoing chet t motherapy for acute leukemia or stem cell transplantat t tion before (n=315) and after (n=302) the introduction of ULR showed a significant reduction in alloimmunit t zation (19% to 7%, P<.001) and in alloimmune platelet refractoriness (14% to 4%, P<.001). Alloimmunization and alloimmune refractoriness in 318 patients who were previously pregnant and/or transfused were also ret t duced after ULR (P=.23 and P=.005, respectively). 
Transfusion-related immunomodulation (TRIM)
Most animal studies using whole blood transfusion have found immunosuppressivetlike responses in ret t cipients, primarily due to the leukocyte content of the donor blood.
107 Moreover, evidence from a variety of sources indicates that allogenic blood transfusion (ABT) enhances the survival of renal allografts, 108 and may increase the recurrence rate of resected malignant t cies, 109 increase the incidence of postoperative bacterial infections, 110t112 reduce the recurrence rate of Crohn' s disease, 113 and reduce the risk of recurrent spontaneous abortion. 114 This clinical syndrome, whose mechanisms still remain to be defined, has been referred to in the transfusion medicine literature as transfusiontrelated immunomodulation (TRIM).
115
TRIM and surgery. The value of leukoreduction for preventing postoperative complications in patients unt t dergoing surgery has been investigated in many obsert t vational studies as well as in 12 randomized controlled trials, which were recently the subject of a metatanalysis that looked at the association between allogenic blood transfusion and postoperative infection. The hypothesis of homogeneity was rejected across the 12 trials (P<.01 for the Qttest statistic). When the ret t sults were combined under conditions of heterogenet t ity, the effect of the WBCtcontaining allogenic blood transfusion on postoperative infection did not quite attain statistical significance (summary OR=1.24; 95% CI, 0·98t1·56; P>.05). Four of these trials showed an increased association between allogenic blood transfut t sion and postoperative infection, but the others did not (Figure 1) . 116, 120, 122, 123 One possible explanation for the lack of consistency among the trials is that the TRIM effect may in fact be quite small (i.e. less than 10%). 8 Vamvakas and Blajchman have postulated that to det t tect a 5% to 10% reduction in the risk of postoperative infection, a randomized trial enrolling 10 000 to 20 000 subjects would be required. Such a study has not been done and is unlikely to be done in the foreseeable fut t ture. 126 There is also evidence that the use of leukoreduced blood components is associated with improvement in morbidity and mortality in cardiac surgery. 110,119,121t123t 125 A randomized trial involving a large series of patients in whom the mortality rate was 50% less in patients ret t ceiving leukoreduced blood also reported a significantly lower postoperative infection rate. 110 The findings of this large study suggest that leukoreduction should be applied for all patients undergoing cardiac surgery in order to improve patient outcome. Figure 2 shows the summary odds ratio of shorttterm mortality in ret t cipients of nontleukocyte reduced versus leukocytetret t duced allogeneic RBCs, from 5 randomized, controlled trials conducted in cardiac surgery. When the 5 trials were studied in a metatanalysis, WBCtcontaining allot t geneic blood transfusion was associated with a 72% int t crease in postoperative mortality (summary OR=0.99; 95% CI, 0.73t1.33; P>.05) compared to patients receivt t ing leukoreduced allogeneic blood.
127
A prospective randomized study by Alexiou et al reported that leukoreduction reduces the numbers of circulating activated leukocytes and pulmonary int t flammations during cardiopulmonary bypass (CPB). 128 Improved lung function and reduced mechanical ventit t lation requirements also have been reported following the use of leukoreduction in patients having abnort t mal preoperative pulmonary function.
129t131 Recently two metatanalyses of 10 randomized, controlled trails evaluated the efficacy and effectiveness of RBC leukot t reduction and demonstrated that patients who were transfused leukoreduced RBCs might benefit from a decrease in postoperative infections. A decrease in mort t tality may have been realized if more patients had been enrolled in the various randomized trials. 132 The results of a retrospective before/after study folt t lowing the institution of ULR in Canada compared cardiac surgery, hip fracture repair, and intensive care unit patients and found decreased mortality, fewer fever episodes, and subsequent use of antibiotics in hightrisk patients (Table 10) .
133 Subsequent reduced length of hospital stay and cost of hospital care may be an adt t ditional financial benefit.
134,135
TRIM and cancer. A higher rate of tumor growth and recurrence with allogenic transfusion and lower rates with leukoreduced ones have been reported in a number of experimental animal model studies.
136,137
Approximately 90 observational studies in man have examined the effect of TRIM on tumor growth prot t motion. 138 Of these, 33 (30 observational and 3 rant t domized, controlled trials) have been in patients with a colorectal malignancy; 14 in patients with a head and neck malignancy; 10 in patients with a breast maligt t nancy; 8 in patients with a gastric malignancy and 8 in Figure 2 : randomized controlled trials (rCTs) conducted in cardiac surgery investigating the association of wbC-containing allogeneic blood transfusion with short-term (up to 3 months post transfusion) mortality from all causes. 127 The odds ratio (Or) of shortterm mortality in recipients of non-wbC-reduced versus wbC-reduced allogeneic rbCs, is shown. These Ors are calculated from intention-to-treat analysis. The figure also shows the summary Ors of short-term mortality across the depicted rCTs, as calculated from a meta-analysis. 110 ,119,121-123 Table 10 . before-after study evaluating the effect of the implementation of universal leukoreduction on various primary and secondary outcomes in 14 786 patients. The three randomized, controlled trials in colorectal cancer patients that compared the incidence of cancer recurrence in recipients of buffy coattreduced allogeneic RBCs with that of recipients of control blood, showed no statistical difference in the incidence of cancer ret t currence. 106, 109, 116 The randomized, controlled trials in human are thus still inconclusive. This may be due to the lack of homogeneity among the studies, the dift t ference in blood component preparation used (buffy coat method versus leukofiltration), multicenter versus single center trials and the type of data analysis by int t vestigators (multivariate versus univariate). Studies in a rabbit allogenic transfusion tumor growth model clearly indicated that buffy coat reduction was associated with a significant reduction in pulmonary tumor nodule fort t mation.
142,143
Transfusion-associated graft-versus-host-disease (TA-GVHD)
TAtGVHD is an infrequent, although almost uniformt t ly fatal complication of blood transfusion, caused by a proliferation of Ttcell lymphocytes derived from the dot t nor. Patients with celltmediated immunodeficiency are at particular risk for TAtGVHD. Another risk group includes patients who have an HLA genotype that is haploidentical with that of the donor. 144 No studies ext t ist investigating the efficacy of leukoreduction for the prevention of TAtGVHD. There are only single case reports and animal studies. 145 These reports conclude that the minimum threshold of transfused lymphot t cytes which prevents the development of TAtGVHD cannot currently be defined.
146t148 A very recent report describes a reduction in reports of TAtGVHD to the United Kingdom Serious Hazards Of Transfusion Program (UK SHOT) since the introduction of ULR in the UK (11 reports of GVHD associated with nont leukoreduced blood components, and only two with the use of leukoreduced blood components). This low rate has occurred with the use of a combination of ULR and the provision of gammatirradiated blood components for patients at risk. 149 The gammatirradiation of blood components has been demonstrated as the best current technology to reduce the risk of TAtGVHD. 150 In any event, most patients who need gammatirradiated blood components also should receive leukoreduced blood components as well. Both measures simultaneously apt t plied in order to prevent TAtGVHD will result in the increased safety of allogeneic transfusions. Another apt t proach might be the use of pathogen inactivation.
151
This report also describes a reduction in cases of postttranst t fusion purpura (PTP) following the introduction of ULR (mean number of reports/year before ULR 10.3; post ULR 2.3).
149
Transfusion-related acute lung injury (TRALI) TRALI is a severe, often fatal, and complex complication of transfusion. TRALI has become the most common cause of transfusiontassociated mortality reported to both the United States Food and Drug Administration (US FDA) and UK SHOT. 14, 15, 151 Although the pathot t physiology of TRALI is not well understood, 152 sevt t eral mechanisms for TRALI have been postulated: Popovsky' s immunetmediated model, 153 in which donor antibodies and less frequently recipient antibodies caust t ing an immune reaction targeting leukocyte antigens and Silliman' s twothit model. 154 In the latter model, the first hit is a physiological insult that activates pulmot t nary endothelium and promotes priming, resulting in the adhesion of neutrophils, (sepsis and trauma). The second hit is an event that activates the neutrophils, causing the release of biological active mediators present in the blood components. 155 If Silliman' s model is valid, pretstorage leukocyte filtration and the use of younger blood components in attrisk patients should reduce the incidence of TRALI. Leukoreduction reduces biologit t cally active mediators associated with prolonged stort t age, 154t158 but whether leukoreduction can reduce the incidence of TRALI is not currently known.
Current international status of ULR
Internationally, 19 countries (Table 11 ) have implet t mented ULR as part of their blood safety policy. Several other countries are also currently moving toward imt t plementing ULR, including Sweden, Denmark, Italy, Belgium, Cyprus and Japan. 159 The motivation to implet t ment ULR varies from one country to another. Some countries, including the United Kingdom and Portugal, decided to adapt ULR in an effort to comply with the precautionary principle concerning the theoretical risk of TAtvCJD. 160 This decision was taken because of evidence that indicated that the pathogenic prion, the causative agent of vCJD, was associated with Btlymt t phocytes. The precautionary principle calls for reducing potential serious risks to public health even if cause and effect relationships are not fully established scientifit t cally. Other countries, such as Germany and Canada, have relied on the evidence of clinical benefit in other clinical areas to justify the adoption of ULR for all transfused patients. In some countries, such as Canada, blood safety is considered paramount, and the use of safer blood components, such as those that are leukot t cyte reduced cannot be restricted and must be applied to all patients. 161 The adoption of ULR in the United States has been delayed primarily because of economic issues, leading to the approach of selective leukocyte reduction protocols for patients thought to be at greatest risk for adverse effects associated with the presence of leukocytes in blood components. The selective patient populations include those who are immunocompromised or chronit t cally transfused. The welltestablished leukocyte medit t ated reactions include febrile reactions (fever), alloimt t munization and its clinically significant consequence known as platelet refractoriness, and transfusion transt t mitted leukocyte associated viruses such as CMV. The differences in practice, belief, and opinion on how best to spend money for blood components has formed the basis for the controversy in the United States over ULR. Both the FDA blood product advisory committ t tee (BPAC) in 1998 and the blood safety and availabilt t ity (BSAC) in 2001 recommended ULR for the United States blood supply. 162, 163 Both the additional cost of ULR and the controversy over the available clinical evidence to support the use of leukoreduction for all patients has delayed implementat t tion of ULR in the United States, despite the BPAC and BSAC recommendations. In fact, the ULR debate has become so politicized that it has become one of the most divisive issues in the history of US transfusion medicine. In 2005, approximately 65% to 70% of the blood supply was leukocyte reduced in the US. 161 It is important to note in this context that many centers and hospitals in the US provide ULR blood components.
At present ULR is practiced in only approximately 20 countries. The main reason for not implementing ULR universally appears to be financial. Other reasons include the opinion that there is not yet sufficient evit t dence to justify adopting the policy of ULR. 164, 165 International experience Hebert et al 133 evaluated clinical outcomes after the adoption of ULR in Canada by conducting a retrot t spective before and after cohort study in 23 academic and community hospitals (n=14 786). Although an increased risk of nosocomial infections was not demont t strated in this trial, inthospital mortality was found to be significantly lower (P=.04) following the introduct t tion of ULR in Canada. 133 The authors of this study indicate that assuming a 7% mortality rate in the cont t trol period, the decreased odds of death based on these results would translate to one life saved for every 120 patients who received leukocyte reduced blood as opt t posed to nontleukoreduced blood. This observation, according to the authors, was consistent among all subt t groups and throughout the range of blood exposures. In addition, this study also found that ULR was associated with a decreased frequency of febrile episodes and subt t sequent use of antibiotics. 133 Fergusson et al 166 evaluated the clinical outcome folt t lowing implementation of a ULR program in premat t ture infants admitted to neonatal intensive care units (NICUs) by conducting a retrospective before and aft t ter study in three Canadian tertiary care NICUs from January 1998 to December 2000. Thus study demont t strated no significant reduction in NICU mortality or bacteremia, but reported an improvement in several clinical outcomes in premature infants requiring RBC transfusions (Table 12) . 166 The authors therefore rect t ommended the adoption of ULR in the care of all low birth weight infants requiring RBC transfusions. Another before and after study (n=2095), conductt t ed in the United Kingdom by Llewelyn et al 167 examt t ined 11 hospitals with patients undergoing cardiac byt t pass surgery or total hip and/or knee replacement and found no impact of ULR on postoperative infections, as reported in the Canadian study, but this study was considerably smaller than the Canadian study (n=2095 versus n=14 786).
Yazer et al, 51 Paglino et al 50 and King et al 52 demt t onstrated that hospitals moving from a selective prot t tocol to ULR had a significantly reduced rate of fevers associated with RBC and platelet transfusions. These fevers occurred in patients who would have been unt t likely to receive leukocyte reduced blood with a select t tive protocol. The difficulty in conducting such studies will increase over time because there are few European countries that do not currently use ULR and because approximately 70% of the blood in the United States is already leukocyte reduced. Finding study sites which will also have a parallel and appropriate control arm to receive nontleukocyte reduced blood is becoming int t creasingly difficult.
Conclusions
The ongoing development of safer transfusion options for use in the care of patients has created many cont t troversies for the field of transfusion medicine. In the debate concerning the implementation of ULR, some experts believe that the clinical benefit for ULR has been shown for many potential recipients who suggest therefore that this technology be applied universally, as the only downside is cost. 168 Others argue that in the absence of data suggesting universal benefit, the techt t nology should be applied only selectively to patients who will clearly benefit. 165 All the data presented in this review clearly indicate that leukoreduction is associated with a reduced risk to patients for some clinical indications, but not for others. In some instances the available evidence is quite strong, but in others the evidence for instituting ULR is not as strong. It is nonetheless clear that ULR does reduce the risk and severity of NHFTRs (level 1 evidence), the risk of CMV transmission (level 1 evidence), and is ast t sociated with a reduced risk of HLA alloimmunization and platelet refractoriness (level 1 evidence). A causal relationship between allogeneic blood transfusions and cancer recurrence seems to be indicated by the obsert t vational studies (level 3 evidence) reported between 1985 and 2000 but not by the available randomized, controlled trials in colorectal cancer patients (level 1 evidence). Specifically, the three available randomized, controlled trials provide no indication that perioperat t tive allogeneic blood transfusion causes an increase in cancer recurrence or death as a result of cancer recurt t rence. Relevant experimental animal studies nonethet t less indicate that allogenic blood transfusions enhance tumor growth promotion in animal models. Concerning whether leukoreduction is associated with a decreased incidence of preoperative mortality and postoperative infections, there is evidence, particularly in patients undergoing cardiac surgery, 125 that the use of leukoret t duced blood components is associated with a decreased risk for bacterial infection (level 1 evidence); reduces the risk of multitorgan dysfunction (level 3 evidence); and most importantly leukoreduction significantly reduces the risk of mortality (level 1 evidence in cardiac surgery patients). 125, 127 Some have noted that there are significant problems with the use of selective transfusion protocols. One problem involves the selection of a patient who might meet the criteria for the selective use of leukoreduction, but who is not being recognized. Such patients thus do not get the best blood component and thus will not bent t efit from this intervention. This could result from phyt t sician ignorance, incomplete hospital databases, or pat t tients undergoing allogeneic transfusions at sites where leukoreduced blood components are not provided.
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What about female patients with multiple pregnant t cies? Transfusion with nontleukocyte reduced blood will likely further alloimmunize them. Does this then represent the mortgaging of their medical future? For example, if certain treatments might be required by such patients, such as kidney allograft transplantation, or the need for chemotherapy to manage a malignancy for which transfusion therapy support might be ret t quired? 161 It seems illogical to support laboratorytbased prot t grams of quality management to reduce the errors and accidents affecting blood transfusion recipients without recognizing that selective transfusion programs are a major source of error. Thus, the implementation of good manufacturing practices and quality initiatives in blood centers and transfusion services will be inherently int t complete until they can assure that transfusion requiret t ments can be met without error. 170 In discussing public policy considerations, Vamvakis, Dzik and Blajchman stated the following: "In the abt t sence of considerations of cost, there is both scientific and medical consensus that leukocyte reduction is apt t propriate medical practice. The WBCs are not a comt t ponent of blood generally intended to be transfused and they can be viewed as undesirable. Furthermore, leukoreduction is almost entirely risk free at least in most situations". 170 Blajchman ended his 1999 editorial by quoting Sir Anthony Bradford Hill, 168 the father of randomized controlled trials: "All scientific work is incomplete, whether it is observational or experimental. All scient t tific work is liable to be upset or modified by advancing knowledge. This does not confer on us a freedom to igt t nore the knowledge we already have, or to postpone the action that it appears to demand at a given time". 171 If zero risk is the goal of transfusion medicine, the legacy from the HIV/HCV experience over the last two decades dictates that all risks should be considered and the resources allocated for each according to priority goals. As important as the direct financial cost is the post t sibility of retdirection of resources away from risks that have already been documented. In this regard it is imt t portant to note that most early manufacturing intervent t tions or changes in practice in transfusion medicine were not introduced based on quality of evidence! Moreover ULR should also be seen as an important processing step that will contribute to improving the safety and purity of blood components. In addition, it can also be seen as an important but necessary preliminary processt t ing step both resulting in safer products for transfusion recipients, but also one that will be required in anticipat t tion of the next new paradigm in transfusion medicine: pathogen inactivation (see Table 1 
